Drug Cos. Nervously Eye High Court In Landmark Case

Law360, New York (May 24, 2006, 12:00 AM EDT) -- One week after the Solicitor General recommended that the Supreme Court deny certiorari in the closely watched Schering-Plough case, the nation’s highest court is still contemplating whether to allow the case to go forward – but the stakes for generic companies, brand-name drug makers and consumers are only getting higher.

In an amicus curiae brief filed last week, the Solicitor General recognized the important issues concerning potential antitrust violations in patent settlements, but recommended against greenlighting the Schering-Plough case, saying it "does not present an appropriate...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.